ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : pathogen response
Australian State/Territory : VIC
Field of Research : Signal Transduction
Clear All
Filter by Field of Research
Signal Transduction (2)
Cell Development, Proliferation and Death (1)
Cellular Immunology (1)
Immunology (1)
Innate Immunity (1)
Reproduction (1)
Filter by Socio-Economic Objective
Disease Distribution and Transmission (incl. Surveillance and Response) (1)
Expanding Knowledge in the Biological Sciences (1)
Health Status (e.g. Indicators of Well-Being) (1)
Infectious Diseases (1)
Preventive Medicine (1)
Reproductive System and Disorders (1)
Filter by Funding Provider
Australian Research Council (1)
National Health and Medical Research Council (1)
Filter by Status
Closed (2)
Filter by Scheme
Discovery Projects (1)
Project Grants (1)
Filter by Country
Australia (2)
Filter by Australian State/Territory
VIC (2)
  • Researchers (1)
  • Funded Activities (2)
  • Organisations (4)
  • Funded Activity

    ROLE OF RIP KINASES & IAPs IN MUCOSAL IMMUNE DEFENCE

    Funder
    National Health and Medical Research Council
    Funding Amount
    $631,168.00
    Summary
    Pathogenic bacteria are master manipulators of the inflammatory signalling pathways designed to thwart them. Understanding how they do this will allow us to develop drugs that limit their ability to infect. We have shown that pathogenic bacteria inject a protein called EspL into human cells to promote the destruction of a family of human proteins, called RIP Kinases (RIPK), that co-ordinate the inflammatory response and aim now to discover how EspL causes RIPK degradation and thereby promotes in .... Pathogenic bacteria are master manipulators of the inflammatory signalling pathways designed to thwart them. Understanding how they do this will allow us to develop drugs that limit their ability to infect. We have shown that pathogenic bacteria inject a protein called EspL into human cells to promote the destruction of a family of human proteins, called RIP Kinases (RIPK), that co-ordinate the inflammatory response and aim now to discover how EspL causes RIPK degradation and thereby promotes infection.
    Read more Read less
    More information
    Funded Activity

    Discovery Projects - Grant ID: DP110103616

    Funder
    Australian Research Council
    Funding Amount
    $600,000.00
    Summary
    The role of a novel protein, interferon epsilon, in reproductive tract immunity. This project aims to develop a world-first description of a new protein that has a protective role against female reproductive tract infections. This unique protein, called interferon epsilon, was discovered in our laboratory. This project will facilitate development of new therapeutic approaches of benefit in diseases such as Chlamydia and Herpes Simplex Virus.
    More information

    Showing 1-2 of 2 Funded Activites

    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback